Romulo Negrini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Romulo Negrini has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Adolfo Wenjaw Liao
Hospital Municipal da Vila Santa Catarina Dr. Gilson de Cássia Marques de Carvalho Hospital Israelita Albert Einstein São Paulo SP Brazil Hospital Municipal da Vila Santa Catarina Dr. Gilson de Cássia Marques de Carvalho; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication Ana Carolina Guimarães Eisencraft
Maternal fetal Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
1 shared publicationAna Paula Avritscher Beck
Maternal fetal Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
1 shared publication- Eduardo Zlotnik
Hospital Israelita Albert Einstein, São Paulo 05652-900, SP, Brazil
1 shared publication - Eduardo Zlotnik
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
1 shared publication Fernanda Paulino Fernandes
Qualidade e Segurança do Paciente, Hospital Israelita Albert Einstein, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
Prioritization of Elective Hysterectomies in the Brazilian Unified Health System: Consistency Between Clinical Risk, Waiting Time and Implications for Surgical Equity
This study examined the consistency between clinical criteria, assigned priority level, and waiting time for elective hysterectomy, assessing whether higher priority translates into faster surgical access. We conducted a retrospective cohort study including 846 women who underwent the procedure between January 2018 and January 2024 at a public hospital in São Paulo, Brazil. The median waiting time was 6 months (IQR: 3–10), with wide variability ranging from 0.5 to 53 months. All components of the clinical score were associated with higher priority levels, demonstrating adequate discriminative ability to identify patients at greater clinical risk. However, assigned priority was not associated with shorter waiting times. Criteria reflecting greater clinical vulnerability, including duration of symptoms (β = +2.50 months), age (β = +1.00), and cardiovascular disease (β = +1.00), were paradoxically associated with longer waiting times, whereas anemia was the only factor associated with reduced waiting time (β = −1.00). These findings reveal a marked discrepancy between formal prioritization and actual surgical scheduling, underscoring the need for more objective and equity-oriented criteria in the management of surgical waiting lists.
Open AccessPrioritization of Elective Hysterectomies in the Brazilian Unified Health System: Consistency Between Clinical Risk, Waiting Time and Implications for Surgical Equity
This study examined the consistency between clinical criteria, assigned priority level, and waiting time for elective hysterectomy, assessing whether higher priority translates into faster surgical access. We conducted a retrospective cohort study including 846 women who underwent the procedure between January 2018 and January 2024 at a public hospital in São Paulo, Brazil. The median waiting time was 6 months (IQR: 3–10), with wide variability ranging from 0.5 to 53 months. All components of the clinical score were associated with higher priority levels, demonstrating adequate discriminative ability to identify patients at greater clinical risk. However, assigned priority was not associated with shorter waiting times. Criteria reflecting greater clinical vulnerability, including duration of symptoms (β = +2.50 months), age (β = +1.00), and cardiovascular disease (β = +1.00), were paradoxically associated with longer waiting times, whereas anemia was the only factor associated with reduced waiting time (β = −1.00). These findings reveal a marked discrepancy between formal prioritization and actual surgical scheduling, underscoring the need for more objective and equity-oriented criteria in the management of surgical waiting lists.
- Open Access
- 29 February 2024
- Published by BMJ in BMJ Open Quality
- Vol. 13 (1) , e002456
Contribution of proactive management of healthcare risks to the reduction of adverse events in a maternity hospital
Background The risks of the childbirth assistance process are still very high, both for mothers and babies. According to the WHO, birth-related asphyxia accounts for 23% of all 3.3 million annual neonatal deaths and an even larger number of survivors with disabilities. On the other hand, maternal mortality is still a global challenge, affecting 17 mothers per 100 000 births in the USA. This is associated with the use of outdated technologies and a lack of well-defined processes in monitoring labour and early recognition of maternal clinical deterioration. Method This study used Lean methodology to map the care flow for pregnant women in a Brazilian maternity hospital (Hospital Israelita Albert Einstein) in order to identify the risks within this process and a set of actions to minimise them. The work team consisted of 29 individuals, including local medical and nursing leaders, as well as healthcare professionals. The What-if tool was used to categorise the levels of risks, and the proportion of severe and catastrophic adverse events was evaluated before and after the implementation of changes. Results After the implementation of the actions, 100% of the extreme risks (28 risks) and 8% of the high risks (4 risks) were eliminated. This led to a reduction in the interval between severe/catastrophic events from 126 to 284 days, even with an increase in the average monthly number of visits from 367 to 449. Consequently, the weighted value of events decreased from 7.91 to 3.29 per 1000 patients treated, resulting in an annual cost savings of R$693 646.80 (US$139 000.00). Discussion The construction of a process based on Lean methodology was essential for mapping the involved risks and implementing a set of actions to minimise them. The participation of the healthcare team and leadership seemed to be important in choosing the measures to be adopted and their applicability. The results found can be attributed to both the established changes and the safety culture brought about by this constructive process.
- 29 February 2024
- Published by BMJ in BMJ Open Quality
- Vol. 13 (1) , e002456
Open AccessContribution of proactive management of healthcare risks to the reduction of adverse events in a maternity hospital
Background The risks of the childbirth assistance process are still very high, both for mothers and babies. According to the WHO, birth-related asphyxia accounts for 23% of all 3.3 million annual neonatal deaths and an even larger number of survivors with disabilities. On the other hand, maternal mortality is still a global challenge, affecting 17 mothers per 100 000 births in the USA. This is associated with the use of outdated technologies and a lack of well-defined processes in monitoring labour and early recognition of maternal clinical deterioration. Method This study used Lean methodology to map the care flow for pregnant women in a Brazilian maternity hospital (Hospital Israelita Albert Einstein) in order to identify the risks within this process and a set of actions to minimise them. The work team consisted of 29 individuals, including local medical and nursing leaders, as well as healthcare professionals. The What-if tool was used to categorise the levels of risks, and the proportion of severe and catastrophic adverse events was evaluated before and after the implementation of changes. Results After the implementation of the actions, 100% of the extreme risks (28 risks) and 8% of the high risks (4 risks) were eliminated. This led to a reduction in the interval between severe/catastrophic events from 126 to 284 days, even with an increase in the average monthly number of visits from 367 to 449. Consequently, the weighted value of events decreased from 7.91 to 3.29 per 1000 patients treated, resulting in an annual cost savings of R$693 646.80 (US$139 000.00). Discussion The construction of a process based on Lean methodology was essential for mapping the involved risks and implementing a set of actions to minimise them. The participation of the healthcare team and leadership seemed to be important in choosing the measures to be adopted and their applicability. The results found can be attributed to both the established changes and the safety culture brought about by this constructive process.
- Open Access
- 2 February 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 20, eRC6550
The use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report
The coronavirus disease 19 (COVID-19) is responsible for the current worldwide pandemic. Treatment and prophylaxis are still under investigation. Convalescent plasma therapy could be an alternative. We report a case of a 41-year-old patient, at 28 weeks of gestation, was hospitalized with COVID-19. On the 10th day after onset of symptoms, the clinical picture worsened, and she required high-flow oxygen therapy (30L/minute), with 92% oxygen saturation, and chest X-ray showing mild bilateral opacities at lung bases. Blood tests showed
- 2 February 2022
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 20, eRC6550
Open AccessThe use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report
The coronavirus disease 19 (COVID-19) is responsible for the current worldwide pandemic. Treatment and prophylaxis are still under investigation. Convalescent plasma therapy could be an alternative. We report a case of a 41-year-old patient, at 28 weeks of gestation, was hospitalized with COVID-19. On the 10th day after onset of symptoms, the clinical picture worsened, and she required high-flow oxygen therapy (30L/minute), with 92% oxygen saturation, and chest X-ray showing mild bilateral opacities at lung bases. Blood tests showed
- RetractedOpen Access
- 24 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219732
The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis
The number of studies associating the use of sildenafil in gestation is increasing. This drug inhibits phosphodiesterase type 5 (PDE5), an enzyme responsible for degradation of nitric oxide, and its efficacy is greater in the placental territory, as the maternal side of the placenta have more PDE5 than other sites. For this reason, promising results have been observed related to the prevention of preeclampsia and intrauterine growth restriction and to improvement of maternal-fetal morbidity in cases of placental insufficiency. To evaluate the benefits of using sildenafil in pregnancy. MEDLINE, ClinicalTrials.gov, Embase, LILACS and Cochrane databases were searched through September 2018. There was no restriction in language or year of publication. This study was registered in PROSPERO (CRD42017060288). Randomized clinical trials which used sildenafil for treatment or prevention of obstetric diseases compared with placebo were selected. The results were obtained using the inverse variance method for continuous variables and Man-Whitney for categorical variables. Among a population of 598 pregnant women from the seven clinical trials included, 139 had pre-eclampsia, 275 had intrauterine growth restriction, and 184 had oligohydramnios. A significant increase of 222.58 grams [27.75 to 417.41] was observed in the fetal weight at birth of patients taking sildenafil. The other outcomes did not show any statistical significance. This may be due to the small number of patients used in each study and the great heterogeneity between the groups. Sildenafil could be associated with increasing fetal weight at birth in placental insufficiency despite the limitations of this meta-analysis, even though more studies in this field are needed to introduce this drug into obstetric clinical practice.
- 24 July 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (7) , e0219732
RetractedOpen AccessThe effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis
The number of studies associating the use of sildenafil in gestation is increasing. This drug inhibits phosphodiesterase type 5 (PDE5), an enzyme responsible for degradation of nitric oxide, and its efficacy is greater in the placental territory, as the maternal side of the placenta have more PDE5 than other sites. For this reason, promising results have been observed related to the prevention of preeclampsia and intrauterine growth restriction and to improvement of maternal-fetal morbidity in cases of placental insufficiency. To evaluate the benefits of using sildenafil in pregnancy. MEDLINE, ClinicalTrials.gov, Embase, LILACS and Cochrane databases were searched through September 2018. There was no restriction in language or year of publication. This study was registered in PROSPERO (CRD42017060288). Randomized clinical trials which used sildenafil for treatment or prevention of obstetric diseases compared with placebo were selected. The results were obtained using the inverse variance method for continuous variables and Man-Whitney for categorical variables. Among a population of 598 pregnant women from the seven clinical trials included, 139 had pre-eclampsia, 275 had intrauterine growth restriction, and 184 had oligohydramnios. A significant increase of 222.58 grams [27.75 to 417.41] was observed in the fetal weight at birth of patients taking sildenafil. The other outcomes did not show any statistical significance. This may be due to the small number of patients used in each study and the great heterogeneity between the groups. Sildenafil could be associated with increasing fetal weight at birth in placental insufficiency despite the limitations of this meta-analysis, even though more studies in this field are needed to introduce this drug into obstetric clinical practice.